Dr. Gregory K. Bell recently testified in three successful challenges to abbreviated new drug applications (ANDA) on behalf of pharmaceutical manufacturers seeking to protect patents covering their products. A key factor in each challenge was how to demonstrate commercial success of the product and the nexus between that success and the patents-in-suit with respect to the issue of non-obviousness of the patents-in-suit.
Dr. Bell was supported in these cases by CRA consultants including Andrew Tepperman, Justin Ho, Cavay Ip, Archan Ruparel, and Natalie Nah.
CRA expands its Intellectual Property Practice
CRA has expanded its Intellectual Property Practice with the addition of 20 consultants including Chris Bakewell and Julia Rowe, who have joined the firm as...